NF-κB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA

Anticancer Research

Volumn 27, Issue 1 A, 2007, Pages 327-334

  Woon, See Tarn ^a   Hung, Sandy S C ^a   Wu, Derek C F ^a   Schooltink, Mary Ann ^a   Sutherland, Rachel ^a   Baguley, Bruce C ^a   Chen, Qi ^b   Chamley, Lawrence W ^b   Ching, Lai Ming ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Anti vascular; Apoptosis; DMXAA; Endothelial; HUVEC; NF B

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; BIOTIN; DEOXYURIDINE TRIPHOSPHATE DERIVATIVE; DNA NUCLEOTIDYLEXOTRANSFERASE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; 5,6 DIMETHYLXANTHENONEACETIC ACID; 5,6-DIMETHYLXANTHENONEACETIC ACID; ANTINEOPLASTIC AGENT; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; UNCLASSIFIED DRUG; XANTHONE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENDOTHELIUM CELL; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; NICK END LABELING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; UPREGULATION; WESTERN BLOTTING; CELL LINE; CYTOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; ENDOTHELIAL CELLS; HUMANS; I-KAPPA B PROTEINS; MUTATION; NF-KAPPA B; TRANSFECTION; XANTHONES;

EID: 33847648543     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Rewcastle GW, Atwell GJ, Li ZA, Baguley BC and Denny WA: Potential antitumour agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34: 217-222, 1991.
2. Rustin GJ, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, Bellenger K, Gumbrell L, Folkes L, Halbert G and UK PIICoCR: 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 88: 1160-1167, 2003.
3. Ching L-M, Cao Z, Kieda C, Zwain S, Jameson MB and Baguley BC: Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone- 4-acetic acid. Br J Cancer 86: 1937-1942, 2002.
4. Ching LM, Zwain S and Baguley BC: Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 90: 906-910, 2004.
5. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Small M, Bellenger K, Gumbrell L, Halbert GW and Kestell P: Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 88: 1844-1850, 2003.
6. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC and Ching L-M: Stimulation of tumours to synthesize tumour necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 59: 633-638, 1999.
7. Ching L-M, Goldsmith D, Joseph WR, Korner H, Sedgwick JD and Baguley BC: Induction of intratumoural tumour necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 59: 3304-3307, 1999.
8. Zhao L, Ching LM, Kestell P and Baguley BC: The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 87: 465-470, 2002.
9. Zwi LJ, Baguley BC, Gavin JB and Wilson WR: The morphological effects of the anti-tumour agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumour. Pathology 26: 161-169, 1994.
10. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ and Wilson WR: Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4- acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78: 439-445, 1998.
11. Wang LC, Woon S-T, Baguley BC and Ching LM: Inhibition of DMXAA-induced rumour necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors. Oncol Res 16: 1-14, 2006.
12. Woon S-T, Baguley BC, Palmer BD, Fraser JD and Ching L-M: Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-κB in human tumour cell lines. Oncol Res 13: 95-101, 2002.
13. Woon S-T, Zwain S, Schooltink MA, Newth A, Baguley BC and Ching L-M: NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Eur J Cancer 39: 1176-1183, 2003.
14. Ching L-M, Young HA, Eberly K and Yu C-R: Induction of STAT and NFkB activation by the antitumour agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line. Biochem Pharmacol 58: 1173-1181, 1999.
15. Aggarwal BB: Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-kappaB. Ann Rheum Dis 59: i6-16, 2000.
16. Barkett M and Gilmore TD: Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 18: 6910-6924, 1999.
17. Kucharczak J, Simmons MJ, Fan Y and Gelinas C: To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 22: 8961-8982, 2003.
18. Matsui K, Fine A, Zhu B, Marshak-Rothstein A and Ju ST: Identification of two NF-kappa B sites in mouse CD95 ligand (Fas ligand) promoter: functional analysis in T cell hybridoma. J Immunol 161: 3469-3473, 1998.
19. Kasibhatla S, Genestier L and Green DR: Regulation of fasligand expression during activation-induced cell death in T lymphocytes via nuclear factor kappaB. J Biol Chem 274: 987-992, 1999.
20. Chan H, Bartos DP and Owen-Schaub LB: Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment. Mol Cell Biol 19: 2098-2108, 1999.
21. Ryan KM, Ernst MK, Rice NR and Vousden KH: Role of NF-kappaB in p53-mediated programmed cell death. Nature 404: 892-897, 2000.
22. Von Albertini M, Palmetshofer A, Kaczmarek E, Koziak K, Stroka D, Grey ST, Stuhlmeier KM and Robson SC: Extracellular ATP and ADP activate transcription factor NF-kappa B and induce endothelial cell apoptosis. Biochem Biophys Res Commun 248: 822-829, 1998.
23. Du X, Stocklauser-Farber K and Rosen P: Generation of reactive oxygen intermediates, activation of NF-kappaB, and induction of apoptosis in human endothelial cells by glucose: role of nitric oxide synthase? Free Radic Biol Med 27: 752-763, 1999.
24. Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J and Kalyanaraman B: Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem J 367: 729-740, 2002.
25. Jaffe EA, Nachman RL, Becker CG and Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. Eur J Clin Invest 52: 2745-2756, 1973.
26. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
27. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-54, 1996.
28. Sen R and Baltimore D: Inducibility of kappa immunoglobulin enhancer-binding protein NF-kappa B by a posttranslational mechanism. Cell 47: 921-928, 1986.
29. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S and Baeuerle PA: Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J 14: 2876-2883, 1995.
30. Hughes SE: Functional characterization of the spontaneously transformed human umbilical vein endothelial cell line ECV304: use in an in vitro model of angiogenesis. Exp Cell Res 225: 171-185, 1996.
31. Suda K, Rothen-Rutishauser B, Gunthert M and Wunderli-Allenspach H: Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: endothelial versus epithelial features. In Vitro Cell Dev Biol Anim 37: 505-514, 2001.
32. Madge LA and Pober JS: TNF signaling in vascular endothelial cells. Exp Mol Pathol 70: 317-325, 2001.
33. Weber C and Erl W: Modulation of vascular cell activation, function, and apoptosis: role of antioxidants and nuclear factor-kappa B. Curr Top Cell Regul 36: 217-235, 2000.
34. Brown K, Gerstberger S, Carlson L, Franzoso G and Siebenlist U: Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 267: 1485-1488, 1995.
35. Karin M and Lin A: NF-kappaB at the crossroads of life and death. Nat Immunol 3: 221-227, 2002.
36. Greten FR and Karin M: The IKK/NF-kappaB activation pathway - a target for prevention and treatment of cancer. Cancer Lett 206: 193-199, 2004.
37. Budihardjo I, Oliver H, Lutter M, Luo X and Wang X: Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15: 269-290, 1999.
38. Janicke RU, Sprengart ML, Wati MR and Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357-9360, 1998.
39. Woo M, Hakem R, Soengas MS, Duncan GS, Shahinian A, Kagi D, Hakem A, McCurrach M, Khoo W, Kaufman SA, Senaldi G, Howard T, Lowe SW and Mak TW: Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 12: 806-819, 1998.
40. Porter AG and Janicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99-104, 1999.
41. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A and Nagata S: A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391: 43-50, 1998.
42. Liu X, Zou H, Slaughter C and Wang X: DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 89: 175-184, 1997.
43. Mitamura S, Ikawa H, Mizuno N, Kaziro Y and Itoh H: Cytosolic nuclease activated by caspase-3 and inhibited by DFF-45. Biochem Biophys Res Commun 243: 480-484, 1998.
44. Tang D and Kidd VJ: Cleavage of DFF-45/ICAD by multiple caspases is essential for its function during apoptosis. J Biol Chem 273: 28549-28552, 1998.
45. Kawane K, Fukuyama H, Yoshida H, Nagase H, Ohsawa Y, Uchiyama Y, Okada K, Iida T and Nagata S: Impaired thymic development in mouse embryos deficient in apoptotic DNA degradation. Nat Immunol 4: 138-144, 2003.
46. Lee YW, Park HJ, Son KW, Hennig B, Robertson LW and Toborek M: 2,2′,4,6,6′-pentachlorobiphenyl (PCB 104) induces apoptosis of human microvascular endothelial cells through the caspase-dependent activation of CREB. Toxicol Appl Pharmacol 189: 1-10, 2003.
47. Yin MJ, Yamamoto Y and Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396: 77-80, 1998.
48. Hehner SP, Hofmann TG, Droge W and Schmitz ML: The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J Immunol 163: 5617-5623, 1999.
49. Kwok BH, Koh B, Ndubuisi MI, Elofsson M and Crews CM: The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 8: 759-766, 2001.